Mexico - Delayed Quote MXN
Eli Lilly and Company (LLY.MX)
14,400.00
-413.00
(-2.79%)
At close: May 9 at 1:44:50 PM CST
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 16 | 15 | 26 | 26 |
Avg. Estimate | 14.32B | 15.37B | 59.61B | 71.36B |
Low Estimate | 13.96B | 14.8B | 58.31B | 65.07B |
High Estimate | 14.85B | 15.95B | 62.38B | 79.04B |
Year Ago Sales | 11.3B | 11.44B | 45.04B | 59.61B |
Sales Growth (year/est) | 26.73% | 34.38% | 32.34% | 19.70% |
EPS Trend
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
LLY.MX | -- | -- | -- | -- |
S&P 500 | 13.21% | 3.06% | 8.01% | 13.77% |
Upgrades & Downgrades
Maintains | UBS: Buy to Buy | 5/2/2025 |
Downgrade | HSBC: Buy to Reduce | 4/28/2025 |
Initiated | Cantor Fitzgerald: Overweight | 4/22/2025 |
Maintains | Guggenheim: Buy to Buy | 4/14/2025 |
Maintains | Morgan Stanley: Overweight to Overweight | 4/9/2025 |
Upgrade | Goldman Sachs: Neutral to Buy | 4/8/2025 |
Related Tickers
SNW.F Sanofi
88.09
-5.27%
AMG.F Amgen Inc.
230.30
-5.34%
NNO2.VI Novo Nordisk A/S
56.60
-4.67%
AZN.L AstraZeneca PLC
9,930.00
-3.03%
NOV.DE Novo Nordisk A/S
56.95
-3.88%
GSK.L GSK plc
1,349.04
-2.07%
BIIB Biogen Inc.
118.17
-0.19%
OGN Organon & Co.
8.71
-3.44%
MRK Merck & Co., Inc.
75.97
-2.16%
JNJ Johnson & Johnson
154.22
-0.93%